

DAFTAR PUSTAKA

1. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection. *Am J Gastroenterol* [Internet]. 2017;112(2):212–38. Available from: <http://dx.doi.org/10.1038/ajg.2016.563>
2. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis. *Gastroenterology* [Internet]. 2017;153(2):420–9. Available from: <http://dx.doi.org/10.1053/j.gastro.2017.04.022>
3. Quach DT, Vilaichone RK, Van Vu K, Yamaoka Y, Sugano K, Mahachai V. *Helicobacter pylori* Infection and Related Gastrointestinal Diseases in Southeast Asian Countries: An Expert Opinion Survey. *Asian Pacific J Cancer Prev*. 2018;19(12):3565–9.
4. PGI, KSHPI. Konsensus Nasional Penatalaksanaan Dispepsia dan Infeksi *Helicobacter pylori* [Internet]. Marcellus Simadibrata K, Dadang Makmun, Murdani Abdullah, Ari Fahrial Syam, Achmad Fauzi, Kaka Renaldi, Hasan Maulahela APU, editor. *Konsensus Nasional Penatalaksanaan Dispepsia dan Infeksi Helicobacter pylori*. 2014. xvi+16 halaman. Available from: <http://pbpgi.or.id/wp-content/uploads/2015/10/Konsensus-Dispepsia-dan-Helicobater-Pylori-2014.pdf>
5. Ozbey G, Dogan Y, Demiroren K, Ozercan IH. Prevalence of *Helicobacter pylori* in Children in Eastern Turkey and Molecular Typing of Isolates. *Brazilian J Microbiol*. 2015;46(2):505–11.
6. Syam AF. Current Situation of *Helicobacter pylori* Infection in Indonesia. *Med J Indones*. 2016;25(4):263–6.
7. Brown LM. *Helicobacter pylori*: Epidemiology and Routes of Transmission. *Epidemiol Rev*. 2000;22(2):283–97.
8. Simadibrata M. *Helicobacter pylori*-related Chronic Gastritis. *Acta Med Indones* [Internet]. 2010;121–2. Available from: [http://www.inaactamedica.org/archives/2010/july/editorial 3-2010.pdf](http://www.inaactamedica.org/archives/2010/july/editorial%203-2010.pdf)

9. Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, et al. Primary Antibiotic Resistance in *Helicobacter pylori* in The Asia-Pacific Region: A Systematic Review and Meta-analysis. *Lancet Gastroenterol Hepatol* [Internet]. 2017;2(10):707–15. Available from: [http://dx.doi.org/10.1016/S2468-1253\(17\)30219-4](http://dx.doi.org/10.1016/S2468-1253(17)30219-4)
10. Miftahussurur M, Syam AF, Nusi IA, Makmun D, Waskito LA, Zein LH, et al. Surveillance of *Helicobacter pylori* Antibiotic Susceptibility in Indonesia: Different Resistance Types Among Regions and with Novel Genetic Mutations. *PLoS One*. 2016;11(12):1–17.
11. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. *Helicobacter pylori* Eradication with Either Seven-day or 10-day Triple Therapies, and with a 10-day Sequential Regimen. *Can J Gastroenterol*. 2006;20(2):113–7.
12. Satria D. Complementary and Alternative Medicine (Cam): Fakta Atau Janji. *Idea Nurs J*. 2013;4(3).
13. KEMENKES. PERMENKES NO. 6 Tahun 2016 Tentang Formularium Obat Herbal Indonesia. 2016;150–2.
14. Nurcholis W, Purwakusumah DE, Rahardjo M, Darusman LK. Variasi Bahan Bioaktif dan Bioaktivitas Tiga Nomor Harapan Temulawak pada Lokasi Budidaya Berbeda. *Jurnal Agron Indones (Indones Journal Agron)*. 2012;XXXIX(2085):153–9.
15. Putri R, Mursiti S, Sumarni W. Aktivitas Antibakteri Kombinasi Temu Putih dan Temulawak terhadap *Streptococcus Mutans*. *J Mipa*. 2017;40(1):43–7.
16. Lee YL, Shim JS, Rukayadi Y, Hwang JK. Antibacterial activity of xanthorrhizol isolated from *Curcuma xanthorrhiza* Roxb. against foodborne pathogens. *J Food Prot*. 2008;71(9):1926–30.
17. Mary HPA, Susheela GK, Jayasree S, Nizzy AM, Rajagopal B, Jeeva S. Phytochemical characterization and antimicrobial activity of *Curcuma xanthorrhiza* Roxb. *Asian Pac J Trop Biomed* [Internet]. 2012;2(2 SUPPL.):S637–40. Available from: <http://dx.doi.org/10.1016/S2221->

- 1691(12)60288-3
18. Kumala S, Rahmat D, Farida Y, Benny. Antibacterial activity of ethanolic extract of javanese turmeric rhizome entrapped in nanoparticles: A novel role of chitosan. *Int J Appl Pharm*. 2018;10(6):298–302.
 19. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, et al. Antimicrobial activity of curcumin against helicobacter pylori isolates from India and during infections in mice. *Antimicrob Agents Chemother*. 2009;53(4):1592–7.
 20. Istiantoro YH, Gan VHS. Penisilin, Sefalosporin dan Antibiotik Betalaktam Lainnya. In: Gunawan SG, editor. *Farmakologi dan Terapi*. 5th ed. Jakarta: FK UI; 2007. p. 664–8.
 21. Istiantoro YH, Gan VHS. Aminoglikosid. In: Gunawan SG, editor. *Farmakologi dan Terapi*. 5th ed. Jakarta: FK UI; 2007. p. 705–17.
 22. Cushnie TPT, Lamb AJ. Antimicrobial activity of Flavonoids. *Int J Antimicrob Agents*. 2005;26(5):343–56.
 23. Dini I, Maryono, Utami N, Hajar S, Hadani A. Evaluation of Antimicrobial Activity and Phytochemical Screening of Chloroform Extract of *Usnea* sp. *ICMSTEA*. 2016;195–9.
 24. Huang Q, Liu X, Zhao G, Hu T, Wang Y. Potential and Challenges of Tannins as an Alternative to In-feed Antibiotics for Farm Animal Production. *Anim Nutr* [Internet]. 2018;4(2):137–50. Available from: <https://doi.org/10.1016/j.aninu.2017.09.004>
 25. Ngadino, Setiawan, Koerniasari, Ernawati, Sudjarwo SA. Evaluation of antimycobacterial activity of *Curcuma xanthorrhiza* ethanolic extract against *Mycobacterium tuberculosis* H37Rv in vitro. *Vet World*. 2018;11(3):368–72.
 26. Coales P. *Principles of Anatomy and Physiology*. Vol. 86, *Physiotherapy*. 2000. 896–939 p.
 27. Smith RS. Junqueira's Basic Histology. Vol. 256, *Journal of the Franklin Institute*. 1953. 595–596 p.
 28. Marshall. *Taxonomy Hierarchy Helicobacter pylori* [Internet]. 1985.

Available from:
https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=962224#null

29. Fleming SL. *Deadly Diseases and Epidemics Helicobacter pylori*. New York: Infobase Publishing; 2007. 43–71 p.
30. Forbes BA, Sahm DF, Weissfeld AS. *Bailey & Scott's Diagnostic Microbiology*. 2016;(July):421–3.
31. Kim J. Culture. In: *Helicobacter pylori*. 2016. p. 129–34.
32. Khalilpour A, Kazemzadeh-Narbat M, Tamayol A, Oklu R, Khademhosseini A. Biomarkers and diagnostic tools for detection of *Helicobacter pylori*. *Appl Microbiol Biotechnol* [Internet]. 2016;100(11):4723–34. Available from: <http://dx.doi.org/10.1007/s00253-016-7495-7>
33. Kuipers EJ. When Is Endoscopic Follow-up Appropriate After *Helicobacter pylori* Eradication Therapy? *Gastroenterol Clin North Am*. 2015 Sep 1;44(3):597–608.
34. FitzGerald R, Smith SM, Clarke AM, Ndip RN. An Overview of Pathogenesis and Epidemiology of *Helicobacter pylori* Infection. *Methods Mol Biol*. 2021;2283(March):1–14.
35. Leodolter A, Kulig M, Braschà H, Meyer-Sabellekà W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with *Helicobacter pylori*-associated gastric or duodenal ulcer. *Aliment Pharmacol Ther*. 2001;15:1949–58.
36. Chey WD, Wong BCY. American College of Gastroenterology Guideline on The Management of *Helicobacter pylori* Infection. *Am J Gastroenterol*. 2007;102(8):1808–25.
37. Setiabudi R. Pengantar Antimikroba. In: Gunawan SG, editor. *Farmakologi dan Terapi*. 5th ed. Jakarta: FK UI; 2007. p. 585–7.
38. Etebu E, Arikekpar I. Antibiotics : Classification and Mechanism of Action with Emphasis on MOlecular Perspective. *Int J Appl Microbiol Biotechnol Res*. 2016;4:90–101.

39. Setiabudy R. Golongan Tetrasiklin dan Kloramfenikol. In: Gunawan SG, editor. *Farmakologi dan Terapi*. 5th ed. Jakarta: FK UI; 2007. p. 694–5.
40. Syamsudin RAMR, Perdana F, Mutiaz FS. Temulawak Plant (*Curcuma xanthorrhiza* Roxb) as a Traditional Medicine. *J Ilm Farm Bahari*. 2019;10(1):51.
41. Rahmat E, Lee J, Kang Y. Javanese Turmeric (*Curcuma xanthorrhiza* Roxb.): Ethnobotany, Phytochemistry, Biotechnology, and Pharmacological Activities. *Evidence-based Complement Altern Med*. 2021;2021.
42. Endarini LH. *Farmakognisi dan Fitokimia*. KEMENKES RI; 2016. 116–118 p.
43. Hwang J, Rukayadi Y. Challenges and opportunities in applying temulawak (*Curcuma xanthorrhiza* Roxb.) for industrial oral care products. *Bogor Agric Univ*. 2006;(July):25–32.
44. Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. *Biomed Res Int*. 2014;2014.
45. Akram M, Ahmed A, Usmanghani K, Hannan A, Mohiuddin E, Asif M. *Curcuma Longa* and Curcumin: a Review Article. *Rom J Biol* [Internet]. 2010;55(2):65–70. Available from: <http://ns.ibiol.ro/plant/volume55/art201.pdf>
46. Blanchard TG, Nedrud JG. Laboratory maintenance of helicobacter species. *Curr Protoc Microbiol*. 2012;(SUPPL.24):1–23.
47. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard*. 11th ed. Vol. 32. USA; 2012. 1–58 p.
48. Kim J. Culture. In: *Helicobacter pylori*. South Korea: Springer; 2016. p. 129–34.
49. Benson. *Microbiological Applications: Laboratory Manual in General Microbiology*. 14th ed. Brown AE, Smith HR, editors. USA: McGraw-Hill Education; 2017. 215–219, 253–269 p.

50. Brink B. Urease Test Protocol. Am Soc Microbiol [Internet]. 2010;(November 2010):1–10. Available from: <http://www.microbelibrary.org/>
51. Laishram S, Pragasam A, Bakthavatchalam Y, Veeraraghavan B. An update on Technical, Interpretative and Clinical Relevance of Antimicrobial Synergy Testing Methodologies. Indian J Med Microbiol. 2017;35(4):445–68.

